The bidding window for Renol Polychem SME IPO was open from July 31, 2025, to August 4, 2025, during which the IPO received 4,12,83,000 bids against 43,50,000 total shares offered. The basis of allotment will be finalised today, August 5, 2025. Here’s how you can check the IPO allotment status.
Renol Polychem IPO is a book-building issue of ₹25.77 crores, consisting entirely of a fresh issue of 24.54 lakh equity shares. The price band is set at ₹105 per share. The tentative listing on NSE Emerge is scheduled for August 7, 2025.
Corporate Makers Capital Ltd. is the book-running lead manager, and Skyline Financial Services is the registrar for the issue.
Check out newly Listed IPOs on BSE and NSE.
The net proceeds from the fresh issue will be used towards the following purposes:
Explore other Upcoming IPOs on BSE and NSE.
(August 4, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
8.41 |
Non-Institutional Investors |
6.89 |
Individual Investors (IND category bidding for 2 Lots) |
6.51 |
Total |
6.83 |
As of 5 August 2025, Renol Polychem IPO’s GMP stood at ₹3. The estimated listing price is ₹108, i.e., a 2.86% gain per share over the upper price band.
Source: Business Standard Report dated 5 August, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Renol Polychem manufactures plastic additives and colour solutions, including colour masterbatches, pigments, filler granules, anti-moisture powder, carbon noodles, superpack & onepack additives, impact modifiers, processing aids, and titanium dioxide.
The company operates on a B2B model and supplies products directly to industrial and commercial enterprises. Renol’s revenue from operations increased from ₹52.26 crore in the financial year ended March 31, 2024, to ₹62.30 crore in the year ended March 31, 2025, reflecting a year-on-year growth of 19.20%.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here